ICMR under process of developing TB Kit
Advertisement
Indian Council for Medical Research (ICMR) is reported to be working on a local diagnostic kit for TB. According to a recent report in the Times of India, the product development has been progressing positively and had entered the final stages of validation.
This diagnostic kit will be local made and as such will also make the TB diagnosis more affordable. As implied by the Director General of ICMR, Dr Soumya Swaminathan, at a symposium on intellectual property in India organised by the Swiss Embassy, this product is expected to bring down the cost of diagnosing TB significantly.
Elaborating further on the product development, Dr Swaminathan has confirmed that this is a joint initiative of the Department of Bio-Technology (DBT), ICMR and the health ministry. The health ministry had earlier expressed their interest in developing an affordable means to diagnose TB, while ensuring the quality of the procedure.
"The health ministry is looking for diagnostics of high quality that is also affordable," said Dr Swaminathan.
Referring to the recent controversy in the US where a company that had a monopoly over a crucial drug hiked its price by 5,500%, Dr Swaminathan said India had to be mindful that companies had that kind of power. The symposium was dominated by those representing Big Pharma interests who emphasised the high costs of drug discovery based on a study by a research centre heavily funded by the pharma industry with pharma-provided data not open to public, as exactly reported by the Times of India.
This diagnostic kit will be local made and as such will also make the TB diagnosis more affordable. As implied by the Director General of ICMR, Dr Soumya Swaminathan, at a symposium on intellectual property in India organised by the Swiss Embassy, this product is expected to bring down the cost of diagnosing TB significantly.
Elaborating further on the product development, Dr Swaminathan has confirmed that this is a joint initiative of the Department of Bio-Technology (DBT), ICMR and the health ministry. The health ministry had earlier expressed their interest in developing an affordable means to diagnose TB, while ensuring the quality of the procedure.
"The health ministry is looking for diagnostics of high quality that is also affordable," said Dr Swaminathan.
Referring to the recent controversy in the US where a company that had a monopoly over a crucial drug hiked its price by 5,500%, Dr Swaminathan said India had to be mindful that companies had that kind of power. The symposium was dominated by those representing Big Pharma interests who emphasised the high costs of drug discovery based on a study by a research centre heavily funded by the pharma industry with pharma-provided data not open to public, as exactly reported by the Times of India.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.